IBT
FATE icon

International Biotechnology Trust’s Fate Therapeutics FATE Stock Holding History

International Biotechnology Trust’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,000
Closed -$464K – 66
2022
Q4 		$464K Sell
46,000
-75,000
-62% -$1.41M 0.14% 59
2022
Q3 		$2.71M Buy
121,000
+117,083
+2,989% +$3.38M 0.87% 35
2022
Q2 		$158K Sell
3,917
-24,083
-86% -$664K 1.65% 20
2022
Q1 		$5.64M Hold
28,000
– – 1.27% 26
2021
Q4 		$1.64M Hold
28,000
– – 0.36% 47
2021
Q3 		$1.66M Buy
+28,000
New +$2.2M 0.4% 44

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

International Biotechnology Trust's FATE Position: Q1 2023 in Review

International Biotechnology Trust sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 46,000 shares — an estimated $464K sold.

International Biotechnology Trust first reported a position in FATE in Q3 2021 and held it in 6 quarters. The position peaked at $5.64M in Q1 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • International Biotechnology Trust reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 46,000 Fate Therapeutics shares in Q1 2023, an estimated $464K.
  • International Biotechnology Trust first reported a position in Fate Therapeutics in Q3 2021 and held it in 6 quarters.
  • International Biotechnology Trust's Fate Therapeutics position peaked at $5.64M in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.